Amgen files update to Tavneos label as FDA escalates push to withdraw
Nicole DeFeudis / endpoints - Amgen has taken steps to update its Tavneos label amid an ongoing battle with the FDA. The company filed a supplement on Wednesday that would add more information to the warning ...
AI Summary: Regulators have intensified scrutiny of Amgen’s Tavneos, weighing withdrawal amid safety and efficacy concerns. Amgen responded by filing a label update as the agency evaluates next steps, setting up a regulatory standoff that could alter patient access and the drug’s commercial fate while investigators review supporting trial data.
Related Stories
Ultragenyx gene therapy becomes first FDA‑approved treatment for ultra‑rare disease / 8 days
Prediction markets wager on drug trials, raising research integrity concerns / 4 wks
US gray‑market peptides face scrutiny as FDA panel debate looms / 1 month
FDA approves first drug treating full spectrum of narcolepsy symptoms / 22 days
FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 3 months
FDA links eight deaths to Amgen’s Tavneos; scrutiny intensifies / 4 months
Denali drug receives accelerated approval for rare CNS indication / 5 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Food Safety, Diagnostics, Pfizer, Product Recall and look for the RSS link.
StackHealth Time Machine